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Abstracts / Osteoarthritis and Cartilage 20 (2012) S10–S53 S47Methods: An oligonucleotide pull-down assay followed by isobaric
mass tag labeling and tandem mass spectrometry was used to isolate
and quantify the proteins binding to each rs143383 allele. Further trans-
acting factors were identiﬁed using TransFac, Promo 3.0 and TESS
prediction software databases, followed by electrophoretic mobility
shift assays (EMSAs). Candidate proteins were investigated further
using antibody supershifts, and their ability to modulate GDF5
expression assessed using RNA interference (RNAi). Luciferase reporter
assays were used to assess the impact of over-expressing candidate
proteins on the transcriptional activity of both rs143383 alleles. Chro-
matin Immunoprecipitation (ChIP) was used to conﬁrm the binding of
these factors to GDF5 in-vivo.
Results: Tandem mass spectrometry identiﬁed the transcriptional co-
activator p15 as binding more avidly to the T-allele of rs143383. Upon
p15 knockdown, overall GDF5 expression increased while the allelic
expression imbalance was attenuated. Furthermore, GDF5 was enriched
following ChIP with an anti-p15 antibody. By EMSA supershift, we
identiﬁed the more avid binding of transcription factors Sp1 and Sp3 to
the T-allele of rs143383. RNAi-mediated silencing of Sp1 and Sp3
signiﬁcantly increased the expression of GDF5, and modulated the AEI
observed. Furthermore, results from ChIP revealed that these two
factors bind GDF5 in-vivo.
Conclusions: p15, Sp1 and Sp3 bind to GDF5, this binding is modulated
by genotype at the rs143383 SNP, and these factors differentially
regulate the expression of GDF5. Now that these trans-acting factors
have been identiﬁed, they can serve as targets for modulating the OA
genetic deﬁcit mediated by rs143383.
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BRAIN FUNCTIONAL PROPERTIES PREDICT PLACEBO ANALGESIA IN
KNEE OSTEOARTHRITIS
A. Mansour, M. Baliki, T.J. Schnitzer, A.V. Apkarian. Northwestern Univ.,
Chicago, IL, USA
Purpose: Chronic pain is the primary complaint associated with OA,
serving as a predictor of physical dysfunction and muscular weakness.
As blinded, randomized placebo-controlled trials of therapeutic agents
in OA have repeatedly demonstrated a marked reduction in pain
response to placebo, studies of the brain response to placebo may
inform on brain properites of OA itself. Although mechanisms of
placebo response have been repeatedly studied in humans, we are the
ﬁrst to investigate its underlying brain properties in a clinical drug
study design. Here we investigate the possibility of identifying brain
properties that predispose different OA patients to placebo analgesia.
Methods: 20 patients meeting ACR criteria for knee OA were enrolled
into this single-blinded 4 week study. At baseline, patients were
instructed that they might be receiving either active drug or placebo;
however they all were given placebo for 2 weeks after which the treat-
mentwas stopped. At baseline and at the end of the 2weeks the patients
underwent an fMRI brain scan as well as a structural high resolution T1
brain scan; efﬁcacy reportswere collected on both occasions. Twoweeks
post cessation of medication patients were contacted again and same
efﬁcacy reports were recollected. The primary efﬁcacy measure was
Visual Analogue Scale 24 hour average pain rating. Secondary efﬁcacy
measures included WOMAC Index; Pain detect, Beck depression Index
(BDI), and Pain catastrophizing scale (PCS). In addition, 17 healthy age-
and gender-matched participants without knee pain were scanned at
baseline to serve as controls. For the analysis, the patient groups were
stratiﬁed as responders vs. non-responders to the placebo treatment
based on a decrease in visual analogue scale (VAS) pain rating equal to or
greater than 20% from baseline. Analysis was then conducted to deter-
mine differences in brain fMRI data between OA patients and controls as
well as betweenOAplacebo-responders vs.OAplacebo-non-responders.
Results: Of the 20 patients enrolled, 9 weremale and 11 female; mean
age was 57.8±6.6 years; mean duration of OA was 12.1±10.0 years.
3 patients discontinued prior to their week 2 visit; of the remainder,
8 responded to placebo (mean VAS dropped from 72.514.1 to
32.520.5, i.e., 56% decrease in VAS) whilst 9 did not show any signiﬁ-
cant change in reported pain (VAS changed from 66.78.2 to 704.7, i.e.,
a mean increase of 7%). OA vs controls: By comparing the general number
of connections across all brain regions between OA patients and controls
we conclude that the region constituted by the medial prefrontal cortex
(mpfc) and nucleus accumbans as well as the caudate is more connected
(p <0.05, corrected for multiplicity) in patients with OA than in controls.
OA-responders vs. OA-non responders: The secondary somatosensorycortex (S2) was generally more linked in the OA non-responders (p-
corrected < 0.05). In this group, the S2 region displayed signiﬁcantly
more connectivity with the ventro-lateral prefrontal cortex (vlpfc).
Moreover, the vlpfc showedmore connectivity (p-corrected< 0.05) with
the part of the brain network identiﬁed for OA, namely mpfc. Both S2
counts and vlpfc-mpfc connectivity predicted with very high accuracy
(AUC¼. 97 and .96, respectively) responders to placebo.
Conclusions: In this study, we have shown that brain information
sharing (functional connectivity) is different in OA in contrast to healthy
control subjects. Furthermore, analysis of activity of components of this
network predicts the response to placebo. Thus, placebo analgesia is
predictable from brain connectivity (information shared between brain
regions), prior to start of the placebo treatment trial. These results
suggest that distinct sub-groups of OA have distinct propensities for
placebo based on their brain states. The speciﬁc characteristics that
distinguish between these groups remains to be identiﬁed. The results
of the present study have important implications regarding OA, clinical
trials in OA, and for future designs of treatments for OA.
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PAIN PERCEPTION IN HAND OSTEOARTHRITIS: RELATION BETWEEN
CLINICAL NODES, RADIOLOGICAL SEVERITY, PAIN THRESHOLD AND
BRAIN PAIN PROCESSING
N.Sofat, J.Wajed, C. Smee,M.Hermansson, F.Howe, T.R. Barrick.StGeorge's,
Univ. of London, London, United Kingdom
Purpose: Hand osteoarthritis (OA) is a prevalent condition for which
treatments are based on analgesia and physical therapies. However, the
majority of patients continue to have symptoms of pain and reduced
function despite optimisation of current available treatments. We
hypothesised that inﬂammation in the hand joints due to osteoarthritis
enhances sensitivity and ﬁring of peripheral nociceptors, thereby
causing chronic pain. Our primary objective was to evaluate pain
perception in a cohort of participants with hand OA by assessing the
characteristics of nodal involvement, pain threshold in each hand joint
and radiological severity. Our secondary objective was to assess if
a standardised painful hand task showed evidence of brain pain pro-
cessing pathways using functional brain neuroimaging.
Methods: Participants with proximal and distal interphalangeal (PIP
and DIP) joint hand OA and non-OA controls were recruited. Clinical
parameters of local joint disease including clinical nodes, VAS (visual
analog score) for pain (0-100 mm scale), HAQ (health assessment
questionnaire), Kellgren-Lawrence scores for radiological severity in
each hand joint (30 regions per hand/subject using standard hand
radiographs and pain thresholds performed with algometers (Wagner
Instruments, USA) over each joint were assessed. Central brain pain
processing in all participants in the cohort was then evaluated using
a standardised ﬁnger ﬂexion-extension task. Subjects underwent
functional brain neuroimaging in a 1.5 Tesla MRI scanner (GE Health-
care) whilst they performed the ﬁnger ﬂexion-extension task to
measure central components of pain processing. Activation of central
pain processing pathways was then evaluated using group analyses
with FMRIB software (www.fmrib.ox.ac.uk/fsl).
Results: All hand OA participants reported pain despite 92% taking oral
analgesic drugs. The mean VAS in hand OA participants was 59.31 mm
+/-8.19 compared with 4.00 mm +/- 1.89 in the control group. Hand OA
participants also had HAQ scores 8-fold higher than controls indicating
high levels of functional impairment (p<0.05).Objectivemeasuresof pain
using algometers on 780 joints in total demonstrated lower pain thresh-
olds across not only DIP and PIP, but also CMC,MCP andwrist joints in the
OAgroupversus controls (p<0.0001). Therewasaglobal reduction inpain
threshold in thehandOAgroupdespite themain radiological changes and
nodal disease being found in the PIP and DIP joints respectively. Pain
threshold in the OA group did not vary signiﬁcantly with increasing
radiological severity. Functional brain MRI during the painful ﬁnger
ﬂexion-extension task demonstrated increased activation of the thal-
amus, cingulate gyrus, frontal and somatosensory cortex in the hand OA
group that was not observed in the control group (p<0.05). The activated
brain regions we observed are known brain pain processing regions.
Conclusions: Our data demonstrate that hand OA subjects are sensi-
tised to pain due to increased ﬁring of peripheral nociceptors. Hand OA
subjects demonstrate lower pain thresholds globally in their hands
compared with controls and have enhanced central sensitisation as
demonstrated by increased activation of central brain pain processing
pathways. Our ﬁndings also suggest that pain processing in OA is
Abstracts / Osteoarthritis and Cartilage 20 (2012) S10–S53S48associated with activation of brain regions mediating emotion and fear
as evidenced by upregulation of the pre-frontal limbic regions in the
hand OA group. Development of future therapies could be targeted at
modulating activation of central pain processing centres in OA to
improve pain management in patients.
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RACIAL DIFFERENCES IN PAIN REPORTING IN SUBJECTS WITH OR AT
RISK FOR SYMPTOMATIC RADIOGRAPHIC KNEE OSTEOARTHRITIS:
DATA FROM THE OSTEOARTHRITIS INITIATIVE
P. Luneburg, L. Yerges-Armstrong, B. Mitchell, M.C. Hochberg. Univ. of
Maryland, Baltimore, MD, USA
Purpose: African Americans have a higher prevalence of both radiographic
and symptomatic radiographic knee OA (KOA) than Caucasian Americans.
While the reasons for this disparity are poorly understood, differences in
risk factor patterns, coping mechanisms, and/or pathoanatomic character-
istics have been suggested. Less is known, however, about differences in
clinical examination features of the knee between the two groups and
whether such differences may explain the greater frequency of pain and
higher pain reporting in African Americans with knee OA.
Methods: Racial differences in pain reporting and severity as well as
ﬁndings on physical examination of the knees were assessed using
baseline data from subjects enrolled in the Osteoarthritis Initiative
(OAI). The OAI is a multicenter, longitudinal observational study initi-
ated in 2004 to examine biomarkers and risk factors for clinically
signiﬁcant knee OA. This analysis included 372 African Americans and
974 Caucasians with symptomatic radiographic KOA in at least one knee
(Progression subcohort) and 495 African Americans and 2703 Cauca-
sians at risk for developing symptomatic radiographic KOA (Incidence
subcohort). In the current analysis, 3 distinct measures of pain severity
(KOOS [0-100], WOMAC [0-20] and NRS [0-10]) and 7 physical exam
ﬁndings were analyzed for each knee initially using bivariate methods
and, subsequently, using multiple variable linear and logistic regression
models, respectively, adjusting for body mass index, age, gender,
income, depression score, and education level.
Results: African Americans reported higher pain severity than Cauca-
sians in both knees for each assessment measure analyzed (BothTable 1
Knee pain by race/ethnicity for subjects in the Incidence and Progression cohorts








3.06 (2.67) 1.85 (2.16) 4.76 (4.76) 3.49 (2.59)
Right knee pain,
WOMAC
3.41 (3.71) 1.50 (2.25) 6.03 (4.37) 3.69 (3.36)
Right knee pain,
KOOS
80.1 (19.0) 89.5 (12.5) 65.4 (21.5) 76.1 (17.7)
Left knee pain, NRS 2.96 (2.88) 1.74 (2.19) 4.60 (3.08) 3.49 (2.76)
Left knee pain,
WOMAC
3.34 (4.08) 1.36 (2.35) 5.80 (4.89) 3.46 (3.62)
Left knee pain,
KOOS
80.8 (20.7) 90.6 (13.0) 67.4 (24.2) 77.7 (19.1)
Table 2
Knee exam ﬁndings by race/ethnicity for subjects in the Incidence and Progression coho
Cohort Incidence
Race/ethnicity African American
Right patellar tendon pain 106 (21.5%)
Right knee ﬂexion pain 83 (16.8%)
Right lateral jointline tender 125 (25.3%)
Right medial jointline tender 137 (27.7%)
Right knee crepitus 185 (37.5%)
Right knee patellar grind 79 (16.2%)
Left patellar tendon pain 102 (20.8%)
Left knee ﬂexion pain 96 (19.5%)
Left lateral jointline tender 116 (23.6%)
Left medial jointline tender 125 (25.4%)
Left knee crepitus 185 (37.6%)
Left knee patellar grind 83 (17.1%)subcohorts: P < 0.0001 for all comparisons) (Table 1). Furthermore,
there were signiﬁcant differences in physical examination ﬁndings
between African Americans and Caucasians for the majority of physical
examination features in both knees in both subcohorts (Table 2). After
adjustment for these differences in physical examination ﬁndings as
well as multiple confounding variables (see above), African-Americans
continued to report greater pain severity than Caucasians both in the
absence of symptomatic radiographic KOA (Incidence subcohort: P <
0.0001 for all pain outcomes) and in the presence of symptomatic
radiographic KOA (Progression subcohort: P < 0.05 for all pain
outcomes except left knee pain in the last 7 days measured by NRS).
Conclusions: These results demonstrate that African Americans report
more pain than Caucasians, even after adjusting for sociodemographic
factors, depressive symptoms and obesity, and that, regardless of the
cause, this difference cannot be explained by ﬁndings on physical exam-
ination. Further analyses should examine the potential role of coping
mechanisms, ﬁndings on magnetic resonance imaging of the knees and
access to both nonpharmacologic and pharmacologic interventions.
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P-188, ANTI-TNF-a AND OP-1: A NOVEL TRIAD IN THE PREVENTION
OF POST-TRAUMATIC OSTEOARTHRITIS
R. Olewinski, A. Hakimiyan, L. Rappoport, C. Pacione, M. Wimmer,
S. Chubinskaya. Rush Univ. Med. Ctr., Chicago, IL, USA
Purpose: This continuing study investigated the utility of individual or
combined pro-anabolic and anti-catabolic biologic interventions tar-
geting chondroprotection and cartilage repair in an ex vivo acute injury
model of post-traumatic osteoarthritis (PTOA) in human ankle cartilage.
Methods: Fifteen normal tali obtained from organ donors through the
Gift of Hope Organ and Tissue Donor Network were impacted using
a 4mm cylindrical indenter with 600N following a model previously
described. 8mm cartilage explants comprising the 4mm impacted
core and the immediately adjacent 4mm non-impacted ring were
cultured for 14 days in the presence of 5% serum and osteogenic
protein-1 (OP-1), two doses of interleukin (IL)-1 receptor antagonist
(IL-RA); tumor necrosis factor-a (TNF-a) antagonist, N-Acetyl-L-
Cysteine (NAC), two pan caspase inhibitors, P-188 surfactant, or the
combination of P-188, OP-1, and anti-TNF-a (Triad). Controls included
untreated impacted and non-impacted explants. Tissue and media
samples were collected on days 0, 2, 7, and 14 to assess cell survival
and metabolic activity. Samples were analyzed for cell viability (live/
dead assay), apoptosis (Tunel assay), matrix integrity (Safranin O
staining, Mankin score), and proteoglycan synthesis and content.
Results: A single impact to human articular cartilage resulted in cell
death/apoptosis within the impacted core, which if untreated, expanded
to the adjacent non-impacted ring. Sustainable signiﬁcant increase in cell
survival was observed under the treatment with OP-1 and more so in
Triad (24% and 43%, p<.001 respectively). These same treatments were
the most signiﬁcant in stimulating PG synthesis (5-fold and 6-fold,
p<.001 respectively). Two of the triad components (TNF-a antagonist
and P-188), when given alone did not show any signiﬁcant effect on PGs.
P-188, OP-1, and TNF-a antagonist in combination showed a better pres-
ervation of matrix integrity as evidenced by normal pattern of Safranin O
staining throughout the entire section. Mankin score was within range of
non-impacted control and was about 2-fold lower than the impactedrts
Incidence Progression Progression
Caucasian African American Caucasian
283 (10.6%) 104 (28.8%) 174 (18.0%)
285 (10.8%) 141 (39.2%) 279 (29.0%)
459 (17.2%) 129 (40.5%) 293 (30.4%)
562 (21.0%) 150 (41.6%) 298 (30.9%)
916 (34.3%) 219 (61.0%) 510 (52.9%)
218 (8.7%) 110 (31.0%) 193 (20.0%)
296 (11.0%) 114 (30.9%) 174 (18.0%)
289 (10.8%) 149 (40.5%) 293 (30.4%)
395 (14.7%) 126 (34.2%) 233 (24.1%)
591 (22.0%) 152 (41.3%) 336 (34.7%)
912 (34.0%) 223 (61.1%) 516 (53.4%)
233 (8.7%) 116 (32.2%) 210 (21.8%)
